ReviewDiscover oncology2025
Review of recent molecular pathology of bladder urothelial carcinoma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder urothelial carcinoma (BUC) is a common malignant tumour with a high recurrence rate and mortality. Research on the molecular pathological basis of BUC is extensive. However, the specific pathogenesis and effective treatment of BUC remain to be further studied. Studies on mutation spectrum, DNA methylation, non-coding RNA, proliferation and apoptosis signalling pathways, cell cycle control, transcription factors, DNA damage repair, immune checkpoint and tumour microenvironment have provided therapeutic strategies for the diagnosis, treatment and prognosis evaluation of BUC. This study provided new insights into the molecular pathology of BUC, helped to improve the diagnosis, treatment and prognostic evaluation of patients and drove the use of precision medicine in the treatment of BUC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.